We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+3.52%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
-$46.5M
Cap. Flow
-$20.4M
Cap. Flow %
-1.21%
Top 10 Hldgs %
61.89%
Holding
89
New
22
Increased
14
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$31.1M
2
BPMC
Blueprint Medicines
BPMC
+$16.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$16.3M
4
ZTS icon
Zoetis
ZTS
+$15.3M
5
ZYME icon
Zymeworks
ZYME
+$13.7M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$25.4M
2
BIIB icon
Biogen
BIIB
+$25.4M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$19.8M
4
PODD icon
Insulet
PODD
+$19.2M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 91.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OBSV
26
DELISTED
ObsEva SA Ordinary Shares
OBSV
$14.8M 0.87%
4,749,623
– –
ZTS icon
27
Zoetis
ZTS
$31.6B
$14.8M 0.87%
+76,000
New +$15.3M
INSM icon
28
Insmed
INSM
$23.2B
$14.7M 0.87%
535,120
-309,049
-37% -$8.11M
SRPT icon
29
Sarepta Therapeutics
SRPT
$1.66B
$14.5M 0.86%
157,279
-141,221
-47% -$10.9M
NCNA
30
NuCana
NCNA
$5.37M
$14.4M 0.86%
1,120
– –
CMPI
31
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$14.3M 0.85%
3,606,707
– –
KURA icon
32
Kura Oncology
KURA
$922M
$14.1M 0.84%
755,121
+310,749
+70% +$5.86M
AGEN
33
Agenus
AGEN
$249M
$12.3M 0.73%
119,448
-21,678
-15% -$2.45M
ZYME icon
34
Zymeworks
ZYME
$1.68B
$11.9M 0.71%
+410,619
New +$13.7M
TVTX icon
35
Travere Therapeutics
TVTX
$5.33B
$10.6M 0.63%
+437,280
New +$8.03M
EXEL icon
36
Exelixis
EXEL
$13.9B
$10.3M 0.61%
488,414
-591,267
-55% -$11M
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$10.1M 0.6%
56,900
-21,638
-28% -$3.48M
BIIB icon
38
Biogen
BIIB
$29.9B
$9.4M 0.56%
33,220
-77,380
-70% -$25.4M
KDMN
39
DELISTED
Kadmon Holdings, Inc.
KDMN
$9.11M 0.54%
+1,046,312
New +$5.96M
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
$8.85M 0.52%
517,708
+52,071
+11% +$811K
CCXI
41
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
$8.65M 0.51%
+505,800
New +$7.88M
PTCT icon
42
PTC Therapeutics
PTCT
$6.37B
$8.56M 0.51%
230,019
-351,921
-60% -$14.5M
ITCI
43
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.48M 0.5%
227,419
-85,740
-27% -$2.98M
ALXO icon
44
ALX Oncology
ALXO
$273M
$7.92M 0.47%
+107,220
New +$7.15M
SNDX icon
45
Syndax Pharmaceuticals
SNDX
$1.84B
$7.91M 0.47%
+413,841
New +$6.9M
CLDX icon
46
Celldex Therapeutics
CLDX
$2.77B
$7.4M 0.44%
137,032
+2,308
+2% +$108K
XLRN
47
DELISTED
Acceleron Pharma
XLRN
$6.81M 0.4%
39,589
-194,049
-83% -$25.4M
IMTX icon
48
Immatics
IMTX
$1.24B
$6.22M 0.37%
478,216
+34,846
+8% +$443K
CTIC
49
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$6.12M 0.36%
2,074,714
+1,903,095
+1,109% +$5.18M
ISEE
50
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.8M 0.34%
+357,400
New +$3.89M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2021 Portfolio in Review

As of Q3 2021, Sofinnova Investments held 89 positions worth $1.69B, down 2.7% from $1.74B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sofinnova Investments's Q3 2021 filing shows 22 new, 14 increased, 20 reduced and 19 closed positions. Its largest new stake was AbbVie: 272,600 shares worth $29.4M. The largest sale was Acceleron Pharma, an estimated $25.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

  • Sofinnova Investments's largest Q3 2021 buy was AbbVie: 272,600 shares worth $29.4M.
  • Sofinnova Investments added most to Heron Therapeutics in Q3 2021, an estimated $10.1M increase.
  • Sofinnova Investments's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $25.4M.
  • Sofinnova Investments fully exited Neurocrine Biosciences in Q3 2021, selling an estimated $19.8M.
  • Sofinnova Investments's ten largest holdings make up 62% of its $1.69B portfolio in Q3 2021.
  • Sofinnova Investments opened 22 new positions and closed 19 in Q3 2021.
  • Sofinnova Investments's portfolio value fell 2.7% quarter-over-quarter to $1.69B.

Based on Sofinnova Investments's 13F filing for Q3 2021, filed 15 Nov 2021.